Symbols

GDRX

Goodrx·NASDAQ

--(--)

GDRX fundamentals

GDRX Q4 2025 Earnings

Goodrx (GDRX) released its earnings on Feb 25, 2026: revenue was 194.78M (YoY -1.91%), beat estimates; EPS was 0.09 (YoY 0.00%), missed estimates.

Revenue / YoY

194.78M

-1.91%

EPS / YoY

0.09

0.00%

Report date

Feb 25, 2026

GDRX Earnings Call Summary for Q4,2025

Pharma Direct Growth: 41% YoY revenue increase in 2025, with 30%+ growth expected in 2026, driven by partnerships like Pfizer and Wegovy pill integration.
Subscription Success: Weight loss subscriptions launched late Q4 2025 captured 20% of Wegovy self-pay fills in January 2026, with 83% QoQ order volume growth.
Strategic Shifts: 6% YoY decline in prescription transactions revenue offset by Pharma Direct growth, with MAC flattening from Q4 2025 to Q4 2026.
Employer Direct Expansion: New offering to help employers subsidize out-of-pocket costs, starting with GLP-1s and expanding to telemedicine solutions.

Earnings

EPS

Revenue

Revenue & Expenses

GDRX has released its 2025 Q4 earnings report, with revenue of 194.78M, reflecting a YoY change of -1.91%, and net profit of 5.42M, showing a YoY change of -19.51%. The Sankey diagram below clearly presents GDRX's revenue sources and cost distribution.

Key Indicators

Goodrx (GDRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Goodrx (GDRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Goodrx (GDRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Goodrx (GDRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown